- Home
- BVS vs DNTH Comparison
BVS vs DNTH Comparison
Compare BVS & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BVS
- DNTH
- Stock Information
- Founded
- BVS 2011
- DNTH 2015
- Country
- BVS United States
- DNTH United States
- Employees
- BVS N/A
- DNTH N/A
- Industry
- BVS Biotechnology: Electromedical & Electrotherapeutic Apparatus
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- BVS Health Care
- DNTH Health Care
- Exchange
- BVS Nasdaq
- DNTH Nasdaq
- Market Cap
- BVS 698.1M
- DNTH 711.2M
- IPO Year
- BVS 2021
- DNTH N/A
- Fundamental
- Price
- BVS $10.04
- DNTH $20.00
- Analyst Decision
- BVS Strong Buy
- DNTH Strong Buy
- Analyst Count
- BVS 3
- DNTH 9
- Target Price
- BVS $15.00
- DNTH $46.43
- AVG Volume (30 Days)
- BVS 345.4K
- DNTH 285.9K
- Earning Date
- BVS 03-11-2025
- DNTH 11-07-2024
- Dividend Yield
- BVS N/A
- DNTH N/A
- EPS Growth
- BVS N/A
- DNTH N/A
- EPS
- BVS N/A
- DNTH N/A
- Revenue
- BVS $555,061,000.00
- DNTH $5,366,000.00
- Revenue This Year
- BVS $11.37
- DNTH $100.14
- Revenue Next Year
- BVS $1.04
- DNTH N/A
- P/E Ratio
- BVS N/A
- DNTH N/A
- Revenue Growth
- BVS 10.40
- DNTH 51.41
- 52 Week Low
- BVS $3.90
- DNTH $11.41
- 52 Week High
- BVS $14.38
- DNTH $33.77
- Technical
- Relative Strength Index (RSI)
- BVS 45.71
- DNTH 37.81
- Support Level
- BVS $8.77
- DNTH $18.35
- Resistance Level
- BVS $10.90
- DNTH $28.65
- Average True Range (ATR)
- BVS 0.50
- DNTH 2.23
- MACD
- BVS 0.03
- DNTH -0.46
- Stochastic Oscillator
- BVS 57.99
- DNTH 16.02
About BVS Bioventus Inc.
Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.